Menu Search
Equities

PharmaSGP Holding SE

PSGX:GER

PharmaSGP Holding SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)23.60
  • Today's Change0.20 / 0.85%
  • Shares traded673.00
  • 1 Year change+22.92%
  • Beta-0.0392
Data delayed at least 15 minutes, as of Nov 25 2024 10:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in EUR

The 2 analysts offering 12 month price targets for PharmaSGP Holding SE have a median target of 38.80, with a high estimate of 39.50 and a low estimate of 38.00. The median estimate represents a 65.81% increase from the last price of 23.40.
High68.8%39.50
Med65.8%38.80
Low62.4%38.00

Dividends

In 2023, PharmaSGP Holding SE reported a dividend of 1.36 EUR, which represents a 177.55% increase over last year. The 2 analysts covering the company expect dividends of 0.64 EUR for the upcoming fiscal year, a decrease of 52.94%.
Div growth (TTM)177.55%
More ▼

Earnings history & estimates in EUR

On Apr 29, 2024, earnings of 0.41 per share. This result exceeded the 0.270 expectation of the one analyst covering the company
The next earnings announcement is expected on Apr 28, 2025.
Average growth rate+11.63%
PharmaSGP Holding SE reported annual 2023 earnings of 1.37 per share on Apr 29, 2024.
Average growth rate+16.45%
More ▼

Revenue history & estimates in EUR

of 25.42m. This bettered the 25.40m estimate of the one analyst covering the company.
Average growth rate+3.93%
PharmaSGP Holding SE had revenues for the full year 2023 of 101.10m. This was 17.80% above the prior year's results.
Average growth rate+17.49%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.